Niraparib for the treatment of ovarian cancer
Sign Up to like & getrecommendations! Published in 2018 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2018.1490180
Abstract: ABSTRACT Introduction: Niraparib, an orally available selective inhibitor of poly(adenosine diphosphate-ribose) polymerase (PARP), is the first PARP inhibitor approved for use in patients with ovarian cancer who do not harbor a germ-line or somatic mutation… read more here.
Keywords: cancer; ovarian cancer; niraparib treatment; treatment ovarian ... See more keywords
Abstract 1724: Evaluation of niraparib in combination with anti-PD1/anti-PD-L1 in preclinical models
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-1724
Abstract: Niraparib is an orally available and selective poly(ADP-ribose) polymerase (PARP)-1/-2 inhibitor approved for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response… read more here.
Keywords: combination; niraparib treatment; treatment; preclinical models ... See more keywords
Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0206
Abstract: We reviewed clinical data for niraparib monotherapy in BRCA-mutated (BRCAm) epithelial ovarian cancer (OC), contextualizing results with data from other poly(ADP-ribose) polymerase inhibitors (PARPis). Niraparib reduced the likelihood of progression or death by 60% as… read more here.
Keywords: brca mutated; niraparib treatment; ovarian cancer; clinical data ... See more keywords